Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ulrika S H Simonsson

Showing results (21-30 of 107) with videos related to

Pageof 11
Sort By:
European Journal of Clinical Pharmacology|June 17, 2010
Population pharmacokinetics of lopinavir in combination with rifampicin-based antitubercular treatment in HIV-infected South African childrenDoaa Elsherbiny, Yuan Ren, Helen McIlleron, et al.
Antimicrobial Agents and Chemotherapy|March 4, 2020
Drug Effect of Clofazimine on Persisters Explains an Unexpected Increase in Bacterial Load in PatientsAlan Faraj, Robin J Svensson, Andreas H Diacon, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|July 31, 2016
Population pharmacokinetics, optimised design and sample size determination for rifampicin, isoniazid, ethambutol and pyrazinamide in the mouseChunli Chen, Fatima Ortega, Laura Alameda, et al.
CPT: Pharmacometrics & Systems Pharmacology|February 1, 2022
A modeling-based proposal for safe and efficacious reintroduction of bedaquiline after dose interruption: A population pharmacokinetics studyLina Keutzer, Yasamin Akhondipour Salehabad, Lina Davies Forsman, et al.
Clinical Pharmacology and Therapeutics|January 4, 2024
Subcutaneous Marzeptacog Alfa (Activated) for On-Demand Treatment of Bleeding Events in Subjects With Hemophilia A or B With InhibitorsAlan Faraj, Joakim Nyberg, Grant E Blouse, et al.
Journal of Pharmacokinetics and Pharmacodynamics|June 4, 2020
A model-based analysis identifies differences in phenotypic resistance between in vitro and in vivo: implications for translational medicine within tuberculosisOskar Clewe, Alan Faraj, Yanmin Hu, et al.
Journal of Pharmacokinetics and Pharmacodynamics|April 24, 2010
A two-compartment effect site model describes the bispectral index after different rates of propofol infusionMarcus A Björnsson, Ake Norberg, Sigridur Kalman, et al.
The Journal of Antimicrobial Chemotherapy|December 26, 2015
A multistate tuberculosis pharmacometric model: a framework for studying anti-tubercular drug effects in vitroOskar Clewe, Linda Aulin, Yanmin Hu, et al.
European Journal of Clinical Pharmacology|August 30, 2008
Population pharmacokinetics of nevirapine in combination with rifampicin-based short course chemotherapy in HIV- and tuberculosis-infected South African patientsDoaa Elsherbiny, Karen Cohen, Britt Jansson, et al.
Antimicrobial Agents and Chemotherapy|October 28, 2005
Population pharmacokinetics of rifapentine and its primary desacetyl metabolite in South African tuberculosis patientsGrant Langdon, Justin Wilkins, Lynn McFadyen, et al.
Pageof 11

Showing results (21-30 of 107) with videos related to

Sort By:
Pageof 11
European Journal of Clinical Pharmacology|June 17, 2010
Population pharmacokinetics of lopinavir in combination with rifampicin-based antitubercular treatment in HIV-infected South African childrenDoaa Elsherbiny, Yuan Ren, Helen McIlleron, et al.
Antimicrobial Agents and Chemotherapy|March 4, 2020
Drug Effect of Clofazimine on Persisters Explains an Unexpected Increase in Bacterial Load in PatientsAlan Faraj, Robin J Svensson, Andreas H Diacon, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|July 31, 2016
Population pharmacokinetics, optimised design and sample size determination for rifampicin, isoniazid, ethambutol and pyrazinamide in the mouseChunli Chen, Fatima Ortega, Laura Alameda, et al.
CPT: Pharmacometrics & Systems Pharmacology|February 1, 2022
A modeling-based proposal for safe and efficacious reintroduction of bedaquiline after dose interruption: A population pharmacokinetics studyLina Keutzer, Yasamin Akhondipour Salehabad, Lina Davies Forsman, et al.
Clinical Pharmacology and Therapeutics|January 4, 2024
Subcutaneous Marzeptacog Alfa (Activated) for On-Demand Treatment of Bleeding Events in Subjects With Hemophilia A or B With InhibitorsAlan Faraj, Joakim Nyberg, Grant E Blouse, et al.
Journal of Pharmacokinetics and Pharmacodynamics|June 4, 2020
A model-based analysis identifies differences in phenotypic resistance between in vitro and in vivo: implications for translational medicine within tuberculosisOskar Clewe, Alan Faraj, Yanmin Hu, et al.
Journal of Pharmacokinetics and Pharmacodynamics|April 24, 2010
A two-compartment effect site model describes the bispectral index after different rates of propofol infusionMarcus A Björnsson, Ake Norberg, Sigridur Kalman, et al.
The Journal of Antimicrobial Chemotherapy|December 26, 2015
A multistate tuberculosis pharmacometric model: a framework for studying anti-tubercular drug effects in vitroOskar Clewe, Linda Aulin, Yanmin Hu, et al.
European Journal of Clinical Pharmacology|August 30, 2008
Population pharmacokinetics of nevirapine in combination with rifampicin-based short course chemotherapy in HIV- and tuberculosis-infected South African patientsDoaa Elsherbiny, Karen Cohen, Britt Jansson, et al.
Antimicrobial Agents and Chemotherapy|October 28, 2005
Population pharmacokinetics of rifapentine and its primary desacetyl metabolite in South African tuberculosis patientsGrant Langdon, Justin Wilkins, Lynn McFadyen, et al.
Pageof 11